![]() | |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C15H15N |
Molar mass | 209.292 g·mol−1 |
3D model ( JSmol) | |
| |
|
Site | IC50 (nM) | Action | Ref |
---|---|---|---|
SERT | 83 nM | Blocker | [1] |
NET | 6 nM | Blocker | [1] |
DAT | 38 nM | Blocker | [1] |
Centanafadine ( INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with an IC50 ratio of 1:6:14, respectively. [1] [2] [3] [4] In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. [5] [6] In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. [7] As of January 2018, Otsuka's pipeline indicates it is in Phase II and III clinical trials for a number of different applications to medical conditions. [8] [9] [10]
{{
cite journal}}
: Cite journal requires |journal=
(
help)
![]() | |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C15H15N |
Molar mass | 209.292 g·mol−1 |
3D model ( JSmol) | |
| |
|
Site | IC50 (nM) | Action | Ref |
---|---|---|---|
SERT | 83 nM | Blocker | [1] |
NET | 6 nM | Blocker | [1] |
DAT | 38 nM | Blocker | [1] |
Centanafadine ( INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with an IC50 ratio of 1:6:14, respectively. [1] [2] [3] [4] In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. [5] [6] In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. [7] As of January 2018, Otsuka's pipeline indicates it is in Phase II and III clinical trials for a number of different applications to medical conditions. [8] [9] [10]
{{
cite journal}}
: Cite journal requires |journal=
(
help)